Icatlo F C, Kimura N, Goshima H, Kodama Y
Immunology Research Institute, Ghen Corporation, Gifu City, Japan.
Antimicrob Agents Chemother. 2000 Sep;44(9):2492-7. doi: 10.1128/AAC.44.9.2492-2497.2000.
The present study investigated the effect of a model urease-binding polysaccharide in combination with a histamine H(2) receptor antagonist on Helicobacter pylori colonization in vivo. Euthymic hairless mice were treated daily with dextran sulfate via drinking water and/or famotidine via intragastric gavage starting at 1 week postchallenge with a CagA(+) VacA(+) (type 1) strain of H. pylori. Treatment of precolonized mice for 2 weeks with dextran sulfate combined with famotidine yielded a group mean bacterial load (per 100 mg of gastric tissue) of log(10) 1.04 CFU, which was significantly lower than those of the famotidine (log(10) 3.35 CFU, P < 0.01) and dextran sulfate (log(10) 2.45 CFU, P < 0.05) monotherapy groups and the infected nontreated group (log(10) 3.64 CFU, P < 0.01). Eradication was achieved after 2 weeks of treatment in 50% or more of the test mice using drug combinations (1 or 2 weeks of famotidine plus 2 weeks of dextran sulfate) versus none in the monotherapy and positive control groups. The enhanced activity of the drug combination may be related to the daily pattern of transient acid suppression by famotidine inducing periodic bacterial convergence to superficial mucus sites penetrated by dextran sulfate from the lumen. Increased urease-dextran sulfate avidity was observed in vitro in the presence of famotidine and may partly account for the enhanced activity. With potential utility in abbreviating treatment time and eradication of antibiotic-resistant strains, the use of urease-targeted polysaccharides concurrently with a gastric acid inhibitor warrants consideration as an additional component of the standard multidrug chemotherapy of H. pylori infection.
本研究调查了一种模型脲酶结合多糖与组胺H₂受体拮抗剂联合使用对体内幽门螺杆菌定植的影响。在感染CagA⁺VacA⁺(1型)幽门螺杆菌菌株1周后,正常胸腺的无毛小鼠每天通过饮用水给予硫酸葡聚糖和/或通过灌胃给予法莫替丁。用硫酸葡聚糖联合法莫替丁对预先定植的小鼠进行2周治疗后,每组平均细菌载量(每100mg胃组织)为log₁₀ 1.04 CFU,显著低于法莫替丁单药治疗组(log₁₀ 3.35 CFU,P < 0.01)、硫酸葡聚糖单药治疗组(log₁₀ 2.45 CFU,P < 0.05)和未治疗的感染组(log₁₀ 3.64 CFU,P < 0.01)。使用药物组合(1或2周的法莫替丁加2周的硫酸葡聚糖)治疗2周后,50%或更多的试验小鼠实现了根除,而单药治疗组和阳性对照组均无此效果。药物组合增强的活性可能与法莫替丁每日短暂抑制胃酸的模式有关,该模式诱导细菌周期性聚集到硫酸葡聚糖从管腔穿透的浅表黏液部位。在法莫替丁存在的情况下,体外观察到脲酶 - 硫酸葡聚糖亲和力增加,这可能部分解释了增强的活性。鉴于在缩短治疗时间和根除抗生素耐药菌株方面具有潜在效用,将脲酶靶向多糖与胃酸抑制剂同时使用作为幽门螺杆菌感染标准多药化疗的附加组成部分值得考虑。